Anthropic Adds Novartis CEO Vas Narasimhan to Board as Trust-Appointed Majority
TL;DR: Anthropic’s Long-Term Benefit Trust has appointed Novartis CEO Vas Narasimhan to the board, tilting the seven-person board to a Trust-appointed majority. Narasimhan is a physician-scientist who has overseen the development and approval of more than 35 new medicines, and his appointment signals Anthropic’s continued positioning around regulated-industry and life-sciences applications.
What This Actually Changes in Governance
Anthropic is a Public Benefit Corporation whose board is elected by stockholders and the Long-Term Benefit Trust, the latter designed to anchor the company to its public-benefit mission rather than pure financial return. Trust-appointed directors now form a majority — Narasimhan joins existing Trust appointees to sit alongside co-founders Dario and Daniela Amodei, Yasmin Razavi, Jay Kreps, Reed Hastings and Chris Liddell. The Trust itself is independent and its members hold no financial stake in Anthropic.
Trust Chair Neil “Buddy” Shah said the Trust specifically sought someone who has stewarded breakthrough science responsibly in a regulated setting. Daniela Amodei framed the appointment around the same mandate, noting that “getting powerful new technology to people safely and at scale” is what Anthropic tries to do every day and something Narasimhan has done in pharma for years.
Why the Life-Sciences Signal Is Unusual
Frontier AI lab boards typically tilt toward tech, finance and policy. A sitting pharma CEO is a different signal. Novartis is one of the world’s largest innovative-medicines companies, and AI is now being applied to early drug discovery across the sector — Reuters this week reported AWS launching its Bio Discovery service for generative drug-molecule workflows, with Bayer, the Broad Institute and Voyager Therapeutics among early adopters. Narasimhan’s appointment brings direct regulated-industry experience to exactly the kind of Anthropic governance decisions that will touch healthcare deployment.
The Broader Context for Anthropic’s Week
The board news arrives in an unusually busy Anthropic news cycle: a restricted release of the Mythos model, Bank of England Governor Andrew Bailey publicly naming Mythos as a cybersecurity concern, co-founder Jack Clark confirming Trump administration briefings, and UK AI Security Institute independent testing showing Mythos differentiated primarily by multi-step attack chaining. Adding a pharma CEO to the governance body at this moment reinforces the framing that Anthropic wants its safety-forward positioning to translate into regulated-sector access.
Looking Forward
For UK healthcare and life-sciences firms, the Narasimhan appointment is a useful read on where Anthropic sees enterprise demand building. Watch for partnership signals with UK-hosted clinical data environments, NHS research compute, and MHRA-adjacent engagement. The governance shift also raises a practical question for procurement teams: when a frontier-lab board prioritises regulated-industry experience, does that ease or complicate compliance conversations? The answer will depend on how Anthropic’s next enterprise contracts are written.